This retrospective analysis investigated the influence of integrative therapies in addition to palliative chemotherapy in patients with advanced pancreatic cancer, treated at a single institution specialized in integrative oncology between January 2015 and December 2019. In total, 206 consecutive patients were included in the study, whereof 142 patients (68.9%) received palliative chemotherapy (gemcitabine/nab-paclitaxel 33.8%; FOLFIRINOX 35.9%; gemcitabine 30.3%) while the remainder were treated with best supportive and integrative care. Integrative therapies were used in 117 of 142 patients (82.4%) in addition to conventional chemotherapy, whereby mistletoe was used in 117 patients (82.4%) and hyperthermia in 74 patients (52.1%). A total of 107/142 patients (86.3%) died during the observation period, whereby survival times differed significantly depending on the additional use of integrative mistletoe or hyperthermia: chemotherapy alone 8.6 months (95% CI 4.7–15.4), chemotherapy and only mistletoe therapy 11.2 months (95% CI 7.1–14.2), or a combination of chemotherapy with mistletoe and hyperthermia 18.9 months (95% CI 15.2–24.5). While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia.
本回顾性分析旨在探讨在姑息化疗基础上联合整合疗法对晚期胰腺癌患者的影响。研究对象为2015年1月至2019年12月期间在某整合肿瘤学专科机构接受治疗的连续病例。共纳入206例患者，其中142例（68.9%）接受姑息化疗（吉西他滨/白蛋白紫杉醇方案33.8%；FOLFIRINOX方案35.9%；吉西他滨单药30.3%），其余患者接受最佳支持治疗联合整合疗法。在142例化疗患者中，117例（82.4%）联合使用了整合疗法，其中槲寄生疗法应用117例（82.4%），热疗应用74例（52.1%）。观察期间共有107/142例（86.3%）患者死亡，生存时间因是否联合整合疗法呈现显著差异：单纯化疗组8.6个月（95% CI 4.7–15.4），化疗联合槲寄生疗法组11.2个月（95% CI 7.1–14.2），化疗联合槲寄生及热疗组18.9个月（95% CI 15.2–24.5）。研究显示，虽然单纯化疗组晚期胰腺癌患者的生存时间与关键III期研究及德国登记数据相符，但联合槲寄生和/或热疗可显著改善患者生存期。
肿瘤(癌症)患者之家